Patients who used copper intrauterine devices were found to have a lower risk of high-grade cervical neoplasms compared to users of the levonorgestrel-releasing intrauterine system, according to a Columbia study recently published in Obstetrics & Gynecology.
Five-year survival rates have improved for young adults with cancer, according to a studyin the Journal of the National Cancer Institute. For some cancers, however, there has been little improvement since the 1970s.
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to the latest edition of Colorectal Cancer Statistics 2020, a publication of the American Cancer Society.
The phase III BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival.
The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.
City of Hope scientists have developed and tested the first chimeric antigen receptor therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published March 4 in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.
Glioblastoma patients with immunologic response to the VBI-1901 vaccine had a higher overall survival rate than non-vaccine responders.
Many patients with rare, fast-growing neuroendocrine tumors respond well to a combination of ipilimumab and nivolumab, according to the first peer-reviewed publication out of DART, a rare cancer clinical trial.
The best approach for surgeons to identify malnourished cancer patients before they have a cancer operation may be related to the cancer type, according to an article published in the Journal of the American College of Surgeons.
The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.
